Document Detail


Uric acid and oxidative stress.
MedLine Citation:
PMID:  16375736     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Uric acid is the final product of purine metabolism in humans. The final two reactions of its production catalyzing the conversion of hypoxanthine to xanthine and the latter to uric acid are catalysed by the enzyme xanthine oxidoreductase, which may attain two inter-convertible forms, namely xanthine dehydrogenase or xanthine oxidase. The latter uses molecular oxygen as electron acceptor and generates superoxide anion and other reactive oxygen products. The role of uric acid in conditions associated with oxidative stress is not entirely clear. Evidence mainly based on epidemiological studies suggests that increased serum levels of uric acid are a risk factor for cardiovascular disease where oxidative stress plays an important pathophysiological role. Also, allopurinol, a xanthine oxidoreductase inhibitor that lowers serum levels of uric acid exerts protective effects in situations associated with oxidative stress (e.g. ischaemia-reperfusion injury, cardiovascular disease). However, there is increasing experimental and clinical evidence showing that uric acid has an important role in vivo as an antioxidant. This review presents the current evidence regarding the antioxidant role of uric acid and suggests that it has an important role as an oxidative stress marker and a potential therapeutic role as an antioxidant. Further well designed clinical studies are needed to clarify the potential use of uric acid (or uric acid precursors) in diseases associated with oxidative stress.
Authors:
G K Glantzounis; E C Tsimoyiannis; A M Kappas; D A Galaris
Related Documents :
18834626 - Association of three genetic loci with uric acid concentration and risk of gout: a geno...
20722406 - Thin-walled graphitic nanocages as a unique platform for amperometric glucose biosensor.
8330466 - Uricosuric effect of cgs-12970, a new thromboxane synthase inhibitor.
2600796 - Pharmacokinetics and biotransformation of hydralazine acetone hydrazone, a metabolite o...
22061946 - Production of cured meat color in nitrite-free harbin red sausage by lactobacillus ferm...
19596196 - Glycolipid ester-type heterodimers from ipomoea tyrianthina and their pharmacological a...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current pharmaceutical design     Volume:  11     ISSN:  1381-6128     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2005  
Date Detail:
Created Date:  2005-12-26     Completed Date:  2006-01-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  4145-51     Citation Subset:  IM    
Affiliation:
University Department of Surgery, Royal Free Hospital, Pond Street, London NW3 2QG, UK. g.glantzounis@medsch.ucl.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antioxidants / pharmacology*
Humans
Laparoscopy
Oxidative Stress*
Reperfusion Injury / metabolism
Uric Acid / pharmacology*
Xanthine Oxidase / physiology
Chemical
Reg. No./Substance:
0/Antioxidants; 69-93-2/Uric Acid; EC 1.17.3.2/Xanthine Oxidase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Uric acid and hypertension.
Next Document:  Uric acid and the kidney: urate transport, stone disease and progressive renal failure.